These trials include the study of ABT-263 in combination with Dabrafenib and Trametinib for the treatment of patients with BRAF mutant melanoma or advanced solid tumors (NCT01989585), and the study of ABT-199 in combination with chemotherapy or pembrolizumab in patients with lung carcinoma (ClinicalTrials.gov Identifiers: NCT04274907, NCT04422210). This evidence concerns the gene BRAF and melanoma.